Yes, Regarding Results it's NO different than the Studies mentioned that shows P3 trials to succeed 60% of the time and then move on to the regulatory filing stage, which has an 80-90% "APPROVAL RATING" https://www.bio.org/sites/default/files/legacy/bioorg/docs/Clinical%20Development%20Success%20Rates%202006-2015%20-%20BIO,%20Biomedtracker,%20Amplion%202016.pdf
Market Data 
Markets 
